The Food and Drug Administration (FDA) has approved Filkri ® (filgrastim-laha), a biosimilar to Neupogen ® (filgrastim). Filkri, a leukocyte growth factor, is approved to: ...

The U.S. Food and Drug Administration (FDA) has approved Filkri (filgrastim-laha), a biosimilar to Neupogen (filgrastim), to ...

The FDA approves biosimilar chemo infection risk treatment Filkri for cancer patients, expanding granulocyte colony-stimulating factor options.

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

The FDA approved a once-monthly Rybrevant Faspro schedule with Lazcluze for first-line EGFR-mutated advanced NSCLC, reducing visits.

The therapy dosing provides clinical outcomes consistent with those of the earlier approved bi-weekly subcutaneous regimen.

Botox is used to treat overactive bladder (OAB) in adults. It’s also approved to treat urinary incontinence caused by certain neurological conditions in adults and children ages 5 years and older. The ...

FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.

The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...